大麻使用与头颈癌
这项大规模多中心队列研究利用64家医疗机构20年数据,对伴有和不伴有大麻相关障碍的美国成人进行倾向评分匹配,发现大麻相关障碍者任何头颈癌风险升高(RR 3.49),口腔癌、口咽癌和喉癌风险亦升高,按年龄分层结果一致。
要点
- 大麻相关障碍者任何头颈癌风险升高(RR 3.49;95%CI 2.78-4.39)。
- 口咽癌风险RR 4.90(95%CI 2.99-8.02),喉癌风险RR 8.39(95%CI 4.72-14.90)。
- 口腔癌风险RR 2.51(95%CI 1.81-3.47),按年龄分层结果一致。
核心结论
- 这项队列研究强调大麻相关障碍与成人头颈癌发生之间存在关联。
- 鉴于数据库的局限性,未来研究应检验该关联的机制并在强对照下分析剂量反应,以进一步支持大麻使用作为头颈癌危险因素的证据。
研究设计与样本
- 大规模多中心队列研究,使用包含64家医疗机构20年数据(截至2024年4月)的数据库临床记录。
- 检索美国成人医疗记录,纳入有门诊就诊记录且无头颈癌既往史、伴或不伴大麻相关障碍者。
- 对大麻相关障碍队列与非大麻相关障碍队列按人口学特征、酒精相关障碍和烟草使用进行倾向评分匹配,计算相对风险(RR)。
主要发现
- 大麻相关障碍队列116 076人(女性51 646人[44.5%]),平均年龄46.4(16.8)岁;非大麻相关障碍队列3 985 286人(女性2 173 684人[54.5%]),平均年龄60.8(20.6)岁。
- 匹配后每组n=115 865,大麻相关障碍者任何头颈癌风险高于对照(RR 3.49;95%CI 2.78-4.39)。
- 部位分析显示大麻相关障碍者口腔癌(RR 2.51;95%CI 1.81-3.47)、口咽癌(RR 4.90;95%CI 2.99-8.02)和喉癌(RR 8.39;95%CI 4.72-14.90)风险更高。
- 按60岁以下和60岁及以上年龄分层,结果一致。
临床怎么用
- 原文未据此给出推荐,结论强调大麻相关障碍与成人头颈癌发生之间存在关联。
局限性
- 原文指出鉴于数据库的局限性,未来研究应检验该关联的机制并在强对照下分析剂量反应,以进一步支持大麻使用作为头颈癌危险因素的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cannabis is the most commonly used illicit substance worldwide. Whether cannabis use is associated with head and neck cancer (HNC) is unclear. OBJECTIVE: To assess the clinical association between cannabis use and HNC. DESIGN, SETTING, AND PARTICIPANTS: This large multicenter cohort study used clinical records from a database that included 20 years of data (through April 2024) from 64 health care organizations. A database was searched for medical records for US adults with and without cannabis-related disorder who had recorded outpatient hospital clinic visits and no prior history of HNC. Propensity score matching was performed for demographic characteristics, alcohol-related disorders, and tobacco use. Subsequently, relative risks (RRs) were calculated to explore risk of HNC, including HNC subsites. This analysis was repeated among those younger than 60 years and 60 years or older. EXPOSURE: Cannabis-related disorder. MAIN OUTCOMES AND MEASURES: Diagnosis of HNC and any HNC subsite. RESULTS: The cannabis-related disorder cohort included 116 076 individuals (51 646 women [44.5%]) with a mean (SD) age of 46.4 (16.8) years. The non-cannabis-related disorder cohort included 3 985 286 individuals (2 173 684 women [54.5%]) with a mean (SD) age of 60.8 (20.6) years. The rate of new HNC diagnosis in all sites was higher in the cannabis-related disorder cohort. After matching (n = 115 865 per group), patients with cannabis-related disorder had a higher risk of any HNC (RR, 3.49; 95% CI, 2.78-4.39) than those without HNC. A site-specific analysis yielded that those with cannabis-related disorder had a higher risk of oral (RR, 2.51; 95% CI, 1.81-3.47), oropharyngeal (RR, 4.90; 95% CI, 2.99-8.02), and laryngeal (RR, 8.39; 95% CI, 4.72-14.90) cancer. Results were consistent when stratifying by older and younger age group. CONCLUSIONS AND RELEVANCE: This cohort study highlights an association between cannabis-related disorder and the development of HNC in adult patients. Given the limitations of the database, future research should examine the mechanism of this association and analyze dose response with strong controls to further support evidence of cannabis use as a risk factor for HNCs.
引用
- Gallagher TJ, Chung RS, Lin ME, et al. Cannabis Use and Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 39115834. doi:10.1001/jamaoto.2024.2419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。